Alexion Pharmaceuticals (NASDAQ: ALXN) is a biopharmaceutical company engaged in the innovation, development, and commercialization of life-transforming therapeutic products to serve patients with severe and ultra-rare disorders. Alexion developed and markets Soliris (eculizumab), which is approved in more than 40 countries to treat PNH and in the U.S. and the European Union for treating aHUS. Other potential indications for Soliris are being evaluated, and Alexion is developing four other highly innovative biotechnology product candidates. For more information, visit the company’s Web site at www.alexionpharma.com

William Blair & Company is a global investment banking and asset management firm committed to building enduring relationships with clients and providing expertise and solutions to meet their evolving needs. An independent and employee-owned firm, William Blair is based in Chicago, and has office locations in 10 cities, including London, New York, Shanghai, and Zurich. For more information on William Blair & Company, visit www.williamblair.com

Let us hear your thoughts below: